Figure 3
MM1S Heca452-positive cells give rise to a more aggressive disease compared to the parental cells. (a) Seven-week-old female scid mice were injected i.v. with 5 × 105 MM1s parental (blue) or MM1s Heca452 variant (red) myeloma cells (n=8 mice per cell line) and the animals were observed daily for clinical signs of tumor progression (morbidity and weight loss). The results are summarized as percent survival over time. P-value was calculated using the Log-rank (Mantel–Cox) test. Seven-week-old female scid mice were injected i.v. with 5 × 106 MM1s parental (b) or MM1s Heca452 variant (c) myeloma cells and beginning 5 days post tumor injection were treated i.p. over 21 days with daily saline alone (red line); daily 40 mg/kg GMI-1271 alone (blue line); once weekly 0.75 mg/kg Bortezomib alone (black line); or the combination of GMI-1271 and Bortezomib. Mice were observed daily for clinical signs of tumor progression (morbidity and weight loss) and the results are summarized as percent survival over time. The data were analyzed for statistical significance by Tukeys multiple comparisons test. i.v., intravenously.
